#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Ana DiLuciano Email
Associate Director Pharmacovigilance . Sierra Oncology
Vancouver, BC
LocationPrimary Email
How to contact Ana DiLuciano
Join and see Ana's contact info for free!Current Roles
Employees:
34Revenue:
$9.8MAbout
Sierra Oncology is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. Our lead product candidate, SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). We are pursuing an innovative development plan for SRA737, which is currently being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer. SRA737-01 is intended to evaluate SRA737's potential to induce synthetic lethality as monotherapy, while the SRA737-02 is intended to evaluate the combination of SRA737 potentiated by subtherapeutic, low dose gemcitabine. Concurrently, we are conducting preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including PARP inhibitors, as well as with immuno-oncology therapeutics, that may guide a potential next wave of clinical development for our asset, possibly further broadening its therapeutic utility. We are also advancing SRA141, a potent, selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). SRA141 is currently undergoing preclinical research in preparation for an Investigational New Drug Application (IND) submission to the U.S. Food and Drug Administration (FDA).Sierra Oncology Address
1820 Gateway DriveVancouver, BC
CAN